Benchmark Co. Reaffirms “Buy” Rating for Heska Corporation (HSKA)

Heska Corporation (NASDAQ:HSKA)‘s stock had its “buy” rating reiterated by Benchmark Co. in a research report issued to clients and investors on Wednesday, August 9th. They currently have a $120.00 target price on the medical research company’s stock, up from their previous target price of $106.00. Benchmark Co.’s target price indicates a potential upside of 22.71% from the company’s previous close.

A number of other research analysts have also weighed in on HSKA. B. Riley reissued a “neutral” rating and issued a $83.00 price objective on shares of Heska Corporation in a report on Friday, April 28th. Zacks Investment Research lowered Heska Corporation from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 3rd. Aegis started coverage on Heska Corporation in a report on Thursday, June 1st. They set a “buy” rating and a $114.50 target price on the stock. Finally, BidaskClub lowered Heska Corporation from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Heska Corporation currently has an average rating of “Hold” and an average price target of $105.20.

Shares of Heska Corporation (NASDAQ HSKA) opened at 97.79 on Wednesday. The company has a market capitalization of $706.63 million, a P/E ratio of 49.84 and a beta of 0.82. Heska Corporation has a 12-month low of $46.51 and a 12-month high of $115.00. The company has a 50-day moving average price of $101.39 and a 200 day moving average price of $96.52.

Heska Corporation (NASDAQ:HSKA) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $34.30 million for the quarter, compared to analyst estimates of $33.35 million. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The company’s revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.35 earnings per share. On average, equities analysts anticipate that Heska Corporation will post $2.04 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Benchmark Co. Reaffirms “Buy” Rating for Heska Corporation (HSKA)” was reported by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/heska-corporation-hska-rating-reiterated-by-benchmark-co-updated.html.

In other Heska Corporation news, Director Carol Wrenn sold 1,630 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $96.95, for a total transaction of $158,028.50. Following the transaction, the director now owns 6,174 shares in the company, valued at $598,569.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael J. Mcginley sold 11,189 shares of the stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $98.53, for a total value of $1,102,452.17. Following the transaction, the insider now owns 111,877 shares in the company, valued at approximately $11,023,240.81. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,265 shares of company stock worth $2,983,439. 14.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the company. D.A. Davidson & CO. increased its position in shares of Heska Corporation by 0.3% in the second quarter. D.A. Davidson & CO. now owns 1,943 shares of the medical research company’s stock worth $198,000 after buying an additional 5 shares in the last quarter. Alps Advisors Inc. increased its position in shares of Heska Corporation by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,117 shares of the medical research company’s stock worth $522,000 after buying an additional 14 shares in the last quarter. Albion Financial Group UT increased its position in shares of Heska Corporation by 1.3% in the second quarter. Albion Financial Group UT now owns 6,421 shares of the medical research company’s stock worth $655,000 after buying an additional 80 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of Heska Corporation by 4.0% in the second quarter. Louisiana State Employees Retirement System now owns 2,600 shares of the medical research company’s stock worth $265,000 after buying an additional 100 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Heska Corporation by 17.5% in the second quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock worth $116,000 after buying an additional 169 shares in the last quarter. Institutional investors own 79.81% of the company’s stock.

Heska Corporation Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska Corporation (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply